EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A hybrid structure determination approach to investigate the druggability of the nucleocapsid protein of SARS-CoV-2

Giacomo Padroni, Maria Bikaki, Mihajlo Novakovic, Antje C Wolter, Simon H Rüdisser, Alvar D Gossert, Alexander Leitner, Frederic H-T Allain iD

Nucleic Acids Research · 2023

DOI: 10.1093/nar/gkad195 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acids Research, 2023. Verfasst von Giacomo Padroni und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry, Department of Biology, ETH Zurich, Hönggerbergring 64, 8093 Zürich, Switzerland. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Coronavirus Nucleocapsid Proteins, COVID-19 Drug Treatment. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swiss National Science Foundation, SNSF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The pandemic caused by SARS-CoV-2 has called for concerted efforts to generate new insights into the biology of betacoronaviruses to inform drug screening and development. Here, we establish a workflow to determine the RNA recognition and druggability of the nucleocapsid N-protein of SARS-CoV-2, a highly abundant protein crucial for the viral life cycle. We use a synergistic method that combines NMR spectroscopy and protein-RNA cross-linking coupled to mass spectrometry to quickly determine the RNA binding of two RNA recognition domains of the N-protein. Finally, we explore the druggability of these domains by performing an NMR fragment screening. This workflow identified small molecule chemotypes that bind to RNA binding interfaces and that have promising properties for further fragment expansion and drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2Coronavirus Nucleocapsid ProteinsCOVID-19 Drug TreatmentDrug DevelopmentHumansRNA, ViralNuclear Magnetic Resonance, BiomolecularMass SpectrometryWorkflowProtein BindingPhosphoproteins

Substanzen

RNA, ViralCoronavirus Nucleocapsid Proteinsnucleocapsid phosphoprotein, SARS-CoV-2Phosphoproteins

Autor:innen und Institutionen

  • Institute of Biochemistry, Department of Biology, ETH Zurich, Hönggerbergring 64, 8093 Zürich, Switzerland.
  • Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Otto-Stern-Weg 3, 8093 Zürich, Switzerland.
  • Biomolecular NMR Spectroscopy Platform, ETH Zurich, Hönggerbergring 64, 8093 Zürich, Switzerland.

ORCID-Profile: Frederic H-T Allain

Förderung

  • Swiss National Science Foundation
  • SNSF

Zitieren

APA

Padroni, G., Bikaki, M., Novakovic, M., Wolter, A. C., Rüdisser, S. H., Gossert, A. D., Leitner, A., & Allain, F. H. (2023). A hybrid structure determination approach to investigate the druggability of the nucleocapsid protein of SARS-CoV-2. Nucleic Acids Research. https://doi.org/10.1093/nar/gkad195

Vancouver

Padroni G, Bikaki M, Novakovic M, Wolter AC, Rüdisser SH, Gossert AD, et al. A hybrid structure determination approach to investigate the druggability of the nucleocapsid protein of SARS-CoV-2. Nucleic Acids Research. 2023. doi:10.1093/nar/gkad195

BibTeX
@article{Padroni2023,
  author = {Padroni, Giacomo and Bikaki, Maria and Novakovic, Mihajlo and Wolter, Antje C and Rüdisser, Simon H and Gossert, Alvar D and Leitner, Alexander and Allain, Frederic H-T},
  title = {A hybrid structure determination approach to investigate the druggability of the nucleocapsid protein of SARS-CoV-2},
  journal = {Nucleic Acids Research},
  year = {2023},
  doi = {10.1093/nar/gkad195}
}
Kostenlos starten →